Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
3,687
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial

Jacob P. Thyssena Department of Dermatology and Venersology, Bispebjerg Hospital, Copenhagen, DenmarkView further author information
,
Thomas Werfelb Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, GermanyView further author information
,
Sebastien Barbarotc Department of Dermatology, Nantes Université, Centre Hospitalier Universitaire de Nantes, Nantes, FranceView further author information
,
Hamish J.A Hunterd Department of Dermatology, Salford Care Organisation, part of the Northern Care Alliance NHS Foundation Trust, Salford, UKView further author information
,
Evangeline Piercee Eli Lilly and Company, Indianapolis, IN, USAView further author information
,
Luna Sune Eli Lilly and Company, Indianapolis, IN, USAView further author information
,
Lisa Cirrie Eli Lilly and Company, Indianapolis, IN, USAView further author information
,
Andrew S. Buchanane Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]
View further author information
,
Na Luf Precision Statistics Consulting, Woodbury, MN, USAView further author information
&
Andreas Wollenbergg Department of Dermatology and Allergy, University Hospital, Ludwig Maximillian University, Munich, GermanyView further author information
 show all
Article: 2190430 | Received 13 Dec 2022, Accepted 09 Mar 2023, Published online: 05 Apr 2023

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Sarah G. Bridgeman, Anna K. Martino & Lindsay C. Strowd. (2023) Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis. Expert Opinion on Pharmacotherapy 0:0, pages 1-7.
Read now

Articles from other publishers (4)

Andreas Wollenberg, Dagmar Simon, Kanokvalai Kulthanan, Ignasi Figueras‐Nart, Laurent Misery, Nithi Tangsirisap, Lara Spina, Na Lu, Susanne Grond & Kilian Eyerich. (2023) Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores. Journal of the European Academy of Dermatology and Venereology.
Crossref
K. Reich, J. I. Silverberg, K. A. Papp, M. Deleuran, N. Katoh, B. Strober, L. A. Beck, M. de Bruin‐Weller, T. Werfel, F. Zhang, P. Biswas, M. D. DiBonaventura, G. Chan, S. A. Farooqui, U. Kerkmann & C. Clibborn. (2023) Abrocitinib effect on patient‐reported outcomes in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study . Journal of the European Academy of Dermatology and Venereology 37:10, pages 2047-2055.
Crossref
M. Munera-Campos & J.M. Carrascosa. (2023) [Translated article] Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives. Actas Dermo-Sifiliográficas 114:8, pages T680-T707.
Crossref
M. Munera-Campos & J.M. Carrascosa. (2023) Inhibidores de JAK en dermatitis atópica, nuevas perspectivas. Actas Dermo-Sifiliográficas 114:8, pages 680-707.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.